The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy
Open accessAbstract
Alemtuzumab for Immune-Related Myocarditis Myocarditis after the use of immune checkpoint inhibitors is a potentially fatal complication. Immune suppression with glucocorticoids is often effective ...
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In cases refractory to steroids, other immunomodulators, including abatacept (a CTLA-4 agonist), alemtuzumab (anti-CD52 antibody), and antithymocyte globulin (antiCD3 antibody) have been used in case reports.”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [261]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B., & Johnson, D. B. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30533-6 · Cited by 942
Immune Checkpoint Inhibitor-Associated Myocarditis
Ganatra, S., & Neilan, T. G. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0130 · Cited by 303
Hughes, M., Lilleker, J. B., Herrick, A. L., & Chinoy, H. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206812 · Cited by 95
Alemtuzumab for Cytolytic Induction of Immunosuppression in Heart Transplant Recipients
Cahoon, W. D., Ensor, C. R., & Shullo, M. A. (2012) · Progress in Transplantation · doi:10.7182/pit2012241 · Cited by 15
Cited by
Sorted by citations
Schneider, B. J., Naidoo, J., Santomasso, B., Lacchetti, C., Adkins, S., Anadkat, M. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01440 · Cited by 2,536
Immune-related adverse events of checkpoint inhibitors
Ramos‐Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N. M., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suarez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,491
Haanen, J. B. A. G., Obéid, M., Spain, L. A., Carbonnel, F., Wang, Y.-S., Robert, C., Lyon, A. R., Wick, W., Kostine, M., Peters, S., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.001 · Cited by 1,454
Immune-checkpoint inhibitors: long-term implications of toxicity
Johnson, D. B., Nebhan, C. A., Moslehi, J. J., & Balko, J. M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00600-w · Cited by 982
Brahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., Gerber, D. E., Hamad, L., Hansen, E., Johnson, D. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002435 · Cited by 917
Metadata
- Authors
- Esfahani, K., Buhlaiga, N., Thébault, P., Lapointe, R., Johnson, N. A., & Miller, W. H.
- Affiliations
- McGill University (CA)
- Université de Montréal (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-06-13
- Volume
- 380
- Issue
- 24
- Pages
- 2375-2376
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2949277199
- Semantic Scholar
- 2f103e1c787c09bd77b6e74d1aecb2033ee5284e
- Cited by
- 224
- References
- 4
- Citations by year
- 2026: 19 · 2025: 14 · 2024: 29 · 2023: 31 · 2022: 36 · 2021: 37 · 2020: 46 · 2019: 9
- FWCI
- 13.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac tumors and thrombi
- Keywords
- alemtuzumab, immune-related myocarditis, PD-1 inhibitors, immune checkpoint inhibitors, immune-related adverse events, glucocorticoid-induced immunosuppression, cardiotoxicity
- MeSH terms
- Antineoplastic Agents, Immunological, Alemtuzumab, Aged, Arrhythmias, Cardiac, Female, Humans, Melanoma, Myocarditis, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
